Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
Thyrocare Recommends Rs 7 Dividend, Re-appoints CEO, and Invests Rs 5.5 Cr in Subsidiary
Thyrocare's board has recommended a final dividend of Rs 7.00 per share, bringing the total FY26 dividend to Rs 9.33 per share post-bonus adjustment. The company is re-appointing Rahul Franklin Guha as CMD & CEO for another five-year term and has approved a fresh investment of up to Rs 5.50 crore in its subsidiary, Think Health Diagnostics. Additionally, the company is broadening its Memorandum of Association to include a wider range of healthcare and digital diagnostic services. Significant board reshuffling also occurred with two resignations and two new appointments of non-executive directors.
Key Highlights
Recommended final dividend of Rs 7.00 per share; total FY26 dividend stands at Rs 9.33 post-bonus adjustmentRe-appointment of Rahul Franklin Guha as CMD & CEO for a 5-year term starting May 2027Approved investment of up to Rs 5.50 crore in wholly-owned subsidiary Think Health Diagnostics Private LimitedAppointment of Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year termProposed MOA changes to broaden business scope into digital platforms and allied healthcare services
👀 What to Watch
Investors should find the dividend payout and leadership continuity as positive indicators of stability. The strategic expansion of the business scope via MOA amendments suggests a long-term growth plan in the digital healthcare ecosystem.
Thyrocare Recommends ₹7 Final Dividend; Total FY26 Dividend at ₹9.33 per Share
Thyrocare Technologies has recommended a final dividend of ₹7 per equity share for FY 2025-26, bringing the total dividend for the year to ₹9.33 per share post-bonus adjustment. The company also announced a ₹5.50 crore investment in its subsidiary, Think Health Diagnostics, to expand its diagnostic footprint. Significant leadership updates include the five-year re-appointment of Rahul Guha as CMD & CEO and the appointment of Price Waterhouse as Statutory Auditors. Furthermore, the company is amending its Memorandum of Association to broaden its scope in the healthcare and diagnostic ecosystem.
Key Highlights
Recommended final dividend of ₹7.00 per equity share for FY 2025-26Total dividend for FY26 aggregates to ₹9.33 per share after post-bonus adjustmentApproved investment of up to ₹5.50 crore in wholly-owned subsidiary Think Health DiagnosticsRe-appointed Rahul Franklin Guha as CMD & CEO for a 5-year term starting May 2027Appointed Price Waterhouse Chartered Accountants LLP as Statutory Auditors for a 5-year term
👀 What to Watch
Investors should view the consistent dividend payout and leadership continuity as positive signs of stability. The expansion of the company's business objects and investment in subsidiaries suggest a focus on long-term growth in the diagnostic sector.
Thyrocare Q4 FY26 Standalone Net Profit Surges 98.5% YoY to ₹43.58 Cr; Revenue Up 21%
Thyrocare Technologies reported a robust performance for the quarter ended March 31, 2026, with standalone revenue growing 21.2% YoY to ₹210.67 crore. Net profit for the quarter nearly doubled, rising 98.5% YoY to ₹43.58 crore, reflecting strong operational leverage. For the full financial year 2026, the company's net profit reached ₹148.81 crore, a significant 55.4% increase over the previous year's ₹95.78 crore. The company maintained an unmodified audit opinion, signaling healthy financial reporting standards.
Key Highlights
Standalone Revenue for Q4 FY26 rose 21.2% YoY to ₹210.67 crore from ₹173.87 crore.Net Profit for Q4 FY26 jumped 98.5% YoY to ₹43.58 crore compared to ₹21.95 crore in the same period last year.Full-year FY26 Net Profit increased by 55.4% to ₹148.81 crore against ₹95.78 crore in FY25.Annual Revenue from operations grew 22.3% to ₹774.27 crore in FY26.Basic EPS for the full year improved significantly to ₹9.36 from ₹5.98 in the previous fiscal year.
👀 What to Watch
The strong double-digit growth in revenue and substantial margin expansion leading to a profit surge are very positive indicators for the stock. Investors should consider the company's improved profitability and operational efficiency as a sign of strengthening market position in the diagnostic sector.
Thyrocare Q4FY26 PAT Surges 128% YoY to ₹48.7 Cr; Revenue Up 20%
Thyrocare reported a strong Q4FY26 with consolidated revenue growing 20% YoY to ₹223.95 crore, driven by a 21% rise in the pathology segment. Profit After Tax (PAT) saw a massive jump of 128% YoY to ₹48.70 crore, while EBITDA margins improved to 34% from 31% in the previous year's quarter. For the full year FY26, the company achieved a revenue of ₹829.04 crore and a PAT of ₹162.85 crore, reflecting robust volume growth of 23%. The company is also diversifying into high-margin specialty diagnostics like genomics and allergy testing.
Key Highlights
Consolidated Q4FY26 revenue grew 20% YoY to ₹223.95 Cr, while FY26 revenue rose 21% to ₹829.04 Cr.Q4FY26 PAT surged 128% YoY to ₹48.70 Cr; FY26 PAT grew 81% YoY to ₹162.85 Cr.Test volumes increased by 29% YoY in Q4 to 59 million tests, maintaining industry volume leadership.Reported EBITDA grew 31% YoY to ₹75.09 Cr in Q4, with margins expanding to 34%.Expansion into specialty diagnostics with 250+ allergy SKUs and launch of Non-invasive Pre-Natal Testing (NIPT).
👀 What to Watch
Investors should view these results positively as the company demonstrates strong operating leverage and volume-led growth. The entry into high-value genomics and specialty testing provides a long-term catalyst for margin improvement.
Thyrocare Infuses Additional USD 475,000 in Tanzania Subsidiary via CCPS
Thyrocare Technologies has invested an additional USD 475,000 (approx. INR 4.33 Crores) into its subsidiary, Thyrocare Laboratories (Tanzania) Limited. This capital infusion was executed through Compulsorily Convertible Irredeemable Preference Shares (CCPS) to support working capital and business operations. The total investment in the Tanzanian venture now reaches approximately INR 10.02 Crores, against a board-approved limit of INR 15 Crores. While the subsidiary is scaling with a turnover of INR 1.84 Crores in 2025, it currently reports a negative net worth of INR 0.32 Crores.
Key Highlights
Additional investment of USD 475,000 (INR 4.33 Crores) via subscription to CCPS.Total cumulative investment in the Tanzanian subsidiary now stands at INR 10.02 Crores.Thyrocare Tanzania reported a turnover of INR 1.84 Crores for the year ended December 31, 2025.The company maintains a 57.25% equity stake and 100% CCPS holding in the joint venture.Board approval allows for a total investment of up to INR 15 Crores in one or more tranches.
👀 What to Watch
Investors should monitor the turnaround and scaling of the Tanzanian operations, as the subsidiary currently has a negative net worth. While the investment amount is small relative to Thyrocare's balance sheet, it reflects the company's commitment to international expansion.
Thyrocare Q3 FY26: Revenue Grows 18% YoY; Pathology Up 20% with Record 10,300 Franchisees
Thyrocare reported a strong Q3 FY26 with consolidated revenue growing 18% YoY, led by a 20% surge in the pathology segment. The company processed 49.6 million tests, a 22% increase, and expanded its active franchisee base to a record 10,300 partners. While the core franchisee business grew 12%, the partnership and insurance segments saw robust growth of 39% and 70% respectively. Management also highlighted achieving Six Sigma quality standards and the appointment of new leadership to drive further expansion.
Key Highlights
Consolidated revenue grew 18% YoY, with the core pathology business increasing by 20%.Total tests processed rose 22% YoY to 49.6 million, serving 4.5 million patients (up 14% YoY).Active quarterly franchisee base reached an all-time high of 10,300, up from 9,165 in the previous year.Partnership business revenue jumped 39% YoY, while the pre-policy medical checkup segment grew 70%.Achieved Six Sigma quality benchmark with 3.2 complaints per million tests, a 43% YoY improvement.
👀 What to Watch
Investors should monitor the scaling of the partnership business and the path to breakeven for the Tanzania operations. The strong volume growth and record franchisee additions indicate robust market share gains and operational efficiency.
Thyrocare Q3 FY26 Results: Consolidated PAT Jumps 47% YoY to ₹27.9 Cr; Revenue Up 18%
Thyrocare Technologies reported a strong performance for Q3 FY26, with consolidated revenue growing 18% YoY to ₹195.5 crore. The company's profitability saw a significant boost as Reported EBITDA rose 38% YoY to ₹57.6 crore and Profit After Tax (PAT) surged 47% to ₹27.9 crore. Operational metrics remained robust with a 22% increase in tests conducted (49.6 million) and a 14% rise in patient volume. While the radiology segment saw a 7% revenue decline due to strategic exits from non-profitable centers, the core pathology business and partnership segments (up 39%) drove overall growth.
Key Highlights
Consolidated Revenue increased 18% YoY to ₹195.53 crore, driven by 20% growth in standalone pathology.Reported EBITDA grew 38% YoY to ₹57.64 crore, with margins expanding from 25% to 29%.Net Profit (PAT) surged 47% YoY to ₹27.91 crore; excluding exceptional items, PAT grew 80% to ₹34.07 crore.Operational volume reached 49.6 million tests (+22% YoY) and 4.5 million patients (+14% YoY).Partnership revenue grew by 39% YoY, while the active franchisee base expanded by 12% to approximately 10,300.
👀 What to Watch
The company demonstrates strong operational leverage and volume-led growth in its core pathology segment. Investors should maintain a positive outlook given the margin expansion and robust partnership growth, while monitoring the impact of the new brand ambassador on retail market share.
Thyrocare Q3 FY26 Net Profit Rises 37% YoY to ₹26.15 Cr; Revenue Up 20%
Thyrocare Technologies reported a strong performance for the quarter ended December 31, 2025, with revenue from operations growing 19.6% YoY to ₹182.48 crore. Net profit increased by 36.9% YoY to ₹26.15 crore, even after accounting for an exceptional charge of ₹5.97 crore related to new labor code compliance and capital restructuring. The company successfully executed a 2:1 bonus issue during the quarter, which resulted in the allotment of over 10.61 crore new shares. For the nine-month period, the company has shown robust growth with a net profit of ₹105.23 crore compared to ₹73.96 crore in the previous year.
Key Highlights
Revenue from operations increased 19.6% YoY to ₹182.48 crore from ₹152.55 crore.Net Profit grew 36.9% YoY to ₹26.15 crore; 9M FY26 profit stands at ₹105.23 crore.Exceptional item of ₹5.97 crore includes ₹4.01 crore for gratuity adjustments under New Labour Codes.Successfully completed a 2:1 bonus share allotment on December 1, 2025, increasing paid-up capital to ₹159.16 crore.Restated Basic EPS for the quarter stands at ₹1.64 compared to ₹1.18 in the year-ago period.
👀 What to Watch
Investors should take note of the strong double-digit growth in both revenue and profitability, indicating improved operational efficiency. The completion of the bonus issue and the one-time nature of the labor code impact suggest a clean slate for future earnings growth.
Thyrocare Appoints Industry Veteran Rajdeep Panwar as Chief Commercial Officer
Thyrocare Technologies has appointed Mr. Rajdeep Panwar as its Chief Commercial Officer, effective January 05, 2026. Mr. Panwar brings over 21 years of deep industry experience, having held leadership roles at major diagnostic players including Dr. Lal PathLabs, Apollo Diagnostics, and Medanta Labs. His expertise in P&L management and laboratory network expansion is expected to drive the company's commercial growth and market penetration. This appointment strengthens the senior management team as the company looks to scale its diagnostic operations across India.
Key Highlights
Appointment of Mr. Rajdeep Panwar as Chief Commercial Officer effective January 05, 2026Mr. Panwar brings over 21 years of experience in healthcare and diagnostics industry leadershipPrevious experience includes Director at Medanta Labs and roles at Apollo Diagnostics and Dr. Lal PathLabsExpertise spans P&L management, digital diagnostics, and large-scale laboratory network expansionThe appointment was approved by the Board via circular resolution on January 05, 2026
👀 What to Watch
Investors should view this as a positive step in strengthening Thyrocare's commercial leadership; monitor for improvements in market share and network expansion in upcoming quarters.
Thyrocare Appoints Dr. Ramesh Kinha as Chief Operating Officer
Thyrocare Technologies has appointed Dr. Ramesh Kinha as its Chief Operating Officer (COO) effective December 18, 2025. Dr. Kinha is a seasoned professional with over 17 years of experience in the healthcare and diagnostics sector, having previously served as Group Director at Vijaya Diagnostic Centre. His extensive background includes leadership roles at major industry players such as Metropolis Healthcare and SRL Ltd. This appointment is expected to strengthen Thyrocare's operational leadership and strategic execution in the competitive diagnostics market.
Key Highlights
Dr. Ramesh Kinha appointed as Chief Operating Officer effective December 18, 2025Brings over 17 years of experience across major diagnostic firms including Metropolis, SRL, and Vijaya DiagnosticHolds an MBBS, MD in Pathology, and senior management certifications from IIM Nagpur and ISBExpertise spans laboratory services, quality assurance, and organization-wide strategic operations
👀 What to Watch
Investors should monitor how Dr. Kinha's operational expertise impacts the company's efficiency and service quality. This is a positive leadership addition given his deep industry experience and medical background.
Thyrocare Allots 10.61 Crore Bonus Equity Shares in 2:1 Ratio
Thyrocare Technologies has successfully allotted 10,61,07,794 bonus equity shares to eligible shareholders as of the record date, November 28, 2025. The bonus issue was executed in a 2:1 ratio, meaning shareholders received two new shares for every one share held. This corporate action has increased the company's total paid-up share capital from Rs. 53.05 crore to Rs. 159.16 crore. The total number of outstanding equity shares has tripled to 15,91,61,691 shares.
Key Highlights
Allotment of 10,61,07,794 fully paid-up bonus equity shares of Rs. 10 eachBonus ratio of 2:1 implemented for all eligible members as of November 28, 2025Total paid-up share capital increased from 5,30,53,897 to 15,91,61,691 equity sharesPost-bonus paid-up capital value stands at Rs. 159,16,16,910New shares rank pari-passu in all respects with existing equity shares
👀 What to Watch
Investors should account for the tripled share count in their portfolios and note that the stock price has adjusted to reflect the 2:1 bonus. No further action is required as the allotment is now complete.
⚠️How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI
⚡ Free FlashFinance Newsletters
AI-powered market intelligence in your inbox — completely free. Pick your topics; max 1 email per topic per day. Unsubscribe anytime.
✅ Everything below is 100% free — no payment, no card, ever.
🎉
You're subscribed!
A welcome email with your topics is on its way. Want it even faster? Join us on Telegram or WhatsApp:
